Glasgow collaborators visit new Heptares Therapeutics site
Dr Sarah Mancini, Professor Graeme Milligan and Professor Andrew Tobin, all from the Institute of Molecular Cell and Systems Biology, recently visited the new site of Heptares Therapeutics in Granta Park, Cambridge. The visit involved a tour of the company’s new facilities as well as a meeting to discuss the progress of the Opportunities in Receptor Biology for Industrial Translation (known as ORBIT) collaboration.
Dr Mancini a Post Doctoral Research Assistant is funded by the clinical-stage company, which uses proprietary StaR® technology and structure-based drug design capabilities to create novel medicines targeting G protein-coupled receptors, a superfamily of receptors linked to a wide range of human diseases. During the visit, she had the opportunity to present her work to the molecular pharmacology group within Heptares Therapeutics and make plans for her upcoming visit to the company to carry out some research projects.
First published: 10 December 2018